Trilaciclib

CAS no.: 1374743-00-6

Type: API

Usage: Chemotherapy-Induced Myelosuppression (CIM)

Technical description
Trilaciclib is a member of piperazines and a member of pyridines. Trilaciclib inhibitor, indicated to reduce the incidence of chemotherapy induced myelosuppression in patients before topotecan-containing or platinum and etoposide-containing chemotherapy for extensive stage small cell lung cancer.

IUPAC name: 4-[[5-(4-methylpiperazin-1-yl)-2-pyridinyl]amino]spiro[1,3,5,11-tetrazatricyclo[7.4.0.02,7]trideca-2,4,6,8-tetraene-13,1′-cyclohexane]-10-one.

Molecular formula: C₂₄H₃₀N₈O

Molecular Weight: 446.5 g/mol

Class: It is a first-in-class transient inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6 inhibitor) used as a myeloprotective agent.

Synonyms: G1T28 / G1T-28 / G1T 28 / G1T28-1.